

Review on Natural and Synthetic Drugs Used In Gastrointestinal Disorders

Jeslin Mary A, Dhanusha S, Aneesha V, Hardha B*, Senthil Kumar M.

Sree Abirami college of pharmacy, Coimbatore-21

Submitted: 20-10-2023

Accepted: 30-10-2023

ABSTRACT:

Gastrointestinal disorders are the most prevalent health issues have been faced. They frequently present as diarrhoea, abdominal pain, distention, gastrointestinal bleeding, intestinal obstruction, malabsorption, or malnutrition. Synthetic drugs, also known as new psychoactive substances, are intended to mimic the effects of illegal substances currently on the market, including marijuana and cocaine. Natural medicines derived from living things, such as the majority of plants, microbes, and animals. Currently, a number of significant medications exist, such as morphine, atropine, galantamine, etc. have their origins in natural sources, which still serve as good models. Pharmacognosy includes traditional medicine as well, and herbal remedies are still widely used in the majority of third-world nations. Thus, pharmacognosy continues to be well-liked in the pharmaceutical sciences and is essential to the process of discovering new drugs.

KEYWORDS: Gastrointestinal, Natural drug, Gastrointestinal cancer, Synthetic Gastrointestinal agents.

I. INTRODUCTION:

The GI tract can be impacted by a variety of ailments or diseases, which may then influence digestion or general health. It happens when the lower oesophageal sphincter, a ring of muscle fibers that covers the opening to our stomach and keeps food from flowing back up our oesophagus, loses its ability to function properly. As a result, irritation is caused by partially digested food and stomach acid leaking back up the oesophagus.^[1]

Other common causes include smoking, excessive stomach acid production, and overuse of anti-inflammatory medications like aspirin, ibuprofen, or diclofenac. Heartburn and abdominal pain are typical symptoms. While food tends to make gastric ulcers worse, the pain of duodenal ulcers is typically relieved by it. Examples include diarrhoea, constipation, irritable bowel syndrome, nausea, gas, and bloating. When your bowels appear abnormal upon examination and are

dysfunctional, you have structural gastrointestinal diseases. The structural abnormality may occasionally require surgical removal. Haemorrhoids, diverticular disease, colon polyps, colon cancer, and inflammatory bowel disease are a few examples of structural Gastrointestinal diseases that are frequently seen. Gastroenterologists are medical professionals with a focus on gastrointestinal disorders. Colorectal surgeons (proctologists) are surgeons who specialize in gastrointestinal disorders.^[2]

Many medications used to treat Gastrointestinal disorders are ineffective or have unwanted side effects. Herbal medicine is a secure, all-natural alternative that typically has no negative side effects. Herbs are used for their therapeutic and medicinal properties in herbal medicine, which is also known as botanical medicine or phytomedicine. The herbs commonly used are: Astragalus for colds, Chinese angelica is used to treat anaemia, Chinese yam for persistent cough and wheezing, Ginger to increase circulation, Immune system support from ginseng, additionally effective at lowering tension and stress, herbal medicines and holistic treatments can benefit people with GI problems. Additionally effective at preventing illness, maintaining good health, and promoting overall wellbeing is herbal medicine. In the past, natural products and their structural analogues have significantly influenced pharmacotherapy, particularly for the treatment of cancer and infectious diseases.^[3]

Japanese herbal medicines have been used in East Asia for thousands of years. In the treatment of patients with functional gastrointestinal disorders, herbal medicines play a valuable role, according to the review of International Medical Literature. Ineffectiveness or unintended side effects are common among medications used to treat Gastrointestinal motility disorders, and in some cases, this has resulted in the removal of medications from the market. An appealing alternative is herbal medicine. Regarding ingredient quality and quantity. Herbal medications are produced according to standardized procedures.

According to the researchers, a more thorough investigation is needed, particularly in the West, of the health advantages of standardized formulations of herbal medicines. Natural products can also be created through chemical synthesis (both semi synthesis and total synthesis), and by providing difficult synthetic targets, they have been instrumental in the growth of the field of organic chemistry. Drugs classified as synthetic are those that have been artificially altered from naturally occurring drugs and are able to have both therapeutic and psychoactive effects. Synthetic drugs have psychotropic effects in a medical setting that can treat insomnia. The pharmacology and drug effects of most synthetic drugs are unknown due to the dearth of clinical trials and human studies.^[4]

II. NATURAL AGENTS:

2.1 PEPPERMINT OIL (*Mentha piperita*):



(Figure 1: Peppermint oil)

Researchers are considering the potential of peppermint oil (figure 1) play a vital role as an adjuvant therapy or alternative medicine in a variety of diseases because of its long use. The institutional ethics committee issued the clearance, which has the number IBS patients visiting the gastroenterology. Following the acquisition of informed consent, participants who satisfied the study's inclusion and exclusion criteria were included^[5].

The patients who met the inclusion criteria were randomly assigned to groups receiving PO or placebo treatments. In the groups receiving placebo treatments, they were evenly distributed. Patients from both groups had baseline data, and there was no discernible difference between them. The mean age was few years. (Standard deviation), spanning the age range of twenty to fourth. The study found a female preponderance and a predominance of mixed varieties of IBS these findings were in line with those of Cash et al. All study participants were. divided into two groups. Patients who

received treatment had significantly lower scores. After four weeks of treatment, there was also a statistically significant improvement compared between the PO and Placebo treated groups.^[6]

2.2 CARDAMOM (*Elettaria Cardamomum*):



(Figure 2: Cardamom)

Gastrointestinal issues are closely related to stress and inflammation. Additionally, to altering behaviour, chronic inflammation can also result in psychological issues. It is crucial to treat the disease with a single drug therapy because multiple drug therapy not only drives up the cost of care but also complicates the condition. The research has been done on the medicinal *Elettaria cardamomum* (figure 2) plant in order to assess and investigate how it affects depression, inflammation, and stress. Terpeneol, terpinene, cineol, limonene, sabinene, and other constituents are present. The seeds' unique aroma is provided by volatile oil. Myrcene, D-limonene, methylhistamines, -pinene, linalool acetate, terpeneol acetate, and -terpeneol4 are among them. Everywhere in the world, spice is expensive. It is traditionally used to treat infections, bronchial inflammation, digestive issues, and cardiac issues. Whole E fruit^[7] Cardamom purchased from the neighbourhood market, and a voucher specimen is kept in the herbarium of the department of pharmacognosy at the Research Institute of Pharmaceutical Sciences, University of Karachi, Pakistan. The crude extract was obtained using the traditional extraction method, and pharmacological and other studies were then conducted using it. Results of various neuro-pharmacological parameters were displayed on the website. It was clear that a low dose of the drug had a very slight stimulating effect, while a high dose resulted in a stimulatory response followed by a sedative effect. Overall, the extract enhanced the locomotor effect and served as an anxiolytic. Highly significant results were seen as the muscles' strength was first improved and then relaxed. crude E. extract. Cardamom demonstrated a significant analgesic and anti-inflammatory drug. Regarding

the treatment of stress-related stomach problems, its anxiolytic and muscle relaxing effects provide an additional benefit^[7]

2.3 CUMIN (*Cuminum cyminum*):



(Figure 3: Cumin)

Among gastrointestinal disorders, irritable bowel syndrome is one of the most prevalent, characterized by persistent abdominal pain, changes in bowel habits, or both, in the consistency of stools. Unfortunately, there are no specific remedies for IBS relief. There are no known symptoms currently. This pilot study was carried out for evaluation, the effectiveness of cumin extract, a type of herbal medicine used to treat gastrointestinal problems, maladies like bloating and other irritable bowel syndrome symptoms. It served as a propose to conduct this prospective trial. from May to October, research in a gastrointestinal disorder clinic at an academic institution. Few essential ingredients are present in cumin extract. In Iran, Kashan. Study. was approved by the institutional ethics committee. Patients provided their informed consent. Everyone who was a patient had the option to decline. whenever they felt like it, they would study. This is the first to the best of our knowledge. study on the use of cumin extract in irritable bowel syndrome patients. Cumin (figure 3) relieves symptoms related to irritable bowel syndrome, considerably worse symptoms. additional herbal remedies, as well as peppermint oils have been investigated. more efficient in patients with irritable bowel syndrome than the placebo. An investigation into the herb madwort. (*fumitory*) and the turmeric plant *Curcuma Xanthuria*. demonstrated that they cannot reduce the symptoms in. sufferers of irritable bowel syndrome. Fibers, peppermint oil, and antispasmodics are discussed. that *PlantagoPsyllium* was a result of drugs. Research has been done on (*fleawort*). and the subject of research is peppermint oil. and anti-spasmodic

medications can be helpful. within irritable bowel syndrome patients. for a minimum of weeks, not necessarily in succession. that possesses two of these three qualities: relieved with. defecation, accompanied by a shift in frequency. stool, connected to a change in its consistency. stool. There were organic causes of pain in every patient included. were eliminated and laboratory tests, including finished. C-reactive, sedimentation rate, and blood count. A protein and thyroid-stimulating hormone evaluation was performed. The symptoms of IBS can all be reduced with cumin extract. Considering. Cumin administration in irritable bowel syndrome patients due to its low cost and simple availability. has potential financial advantages^[8]

2.4 MILK THISTLE (*Silybum marianum*):



(Figure 4: Milk thistle)

Milk thistle, also known as *Silybum marianum*, is the source of silymarin, which is a mixture of several closely related flavonolignan compounds, including silybin. In both clinical studies and experimental models, silymarin has been shown to protect the liver. Silymarin's chemo preventive activity has demonstrated some effectiveness against cancer in vitro and in vivo. Silymarin (figure 4) can affect apoptosis in vitro and survival in vivo by affecting the expression of proteins associated with apoptosis and cell cycle regulators. Silymarin has been shown to have anti-inflammatory properties in addition to its anti-metastatic properties.^[9]Silymarin and silybin, its main component, have chemoprotective properties that suggest they may be used to improve the anti-cancer effects of radiotherapy and chemotherapy while minimizing their side effects in a variety of cancer types, particularly gastrointestinal cancers. In order to better understand how silymarin works to treat gastrointestinal cancer, this review analyses recent studies and provides a summary of its mechanistic pathways and downstream targets.

We now know more about how food can be used as medicine thanks to recent developments

in epidemiology, molecular biology, and biochemistry. Our eating habits play important roles in maintaining our health, and an unbalanced diet can lead to a few health issues. Antioxidants have been identified as major regulators of numerous physiological pathways, and the antioxidant/pro-oxidant balance (redox balance) in our diet can have an impact on the blood flow and tissues as well as the gastrointestinal system. Natural products contain a vast number of phenolic compounds that are both consumed by humans and other animals. Additionally, various phytochemicals, such as flavonoids, are an essential component of our diet and play a role in preserving the optimal status of our antioxidant defences.^[9]

2.5 GINGER (*Zingiber officinale*):



(Figure 5: Ginger)

Researchers are considering ginger's potential roles as an adjuvant therapy or alternative medicine in a variety of diseases because of its long history of medicinal use. Ginger

(Figure 5) is the rhizome of the *Zingiber officinale* plant, which is used as a spice around the world. Numerous scientific studies have demonstrated the anti-inflammatory, antioxidant, antitumor, and antiulcer properties of ginger, and human studies have supported some of the traditional uses of ginger as a home remedy. We compiled the most recent research on the effects of ginger consumption on gastrointestinal disorders in this review, which was supported by clinical trials. Our results show that few mg of ginger taken in smaller doses throughout the day is helpful for reducing nausea. due to the small number of gastrointestinal studies. disorders, the results may not be as powerful as to find meaningful results. more thorough and carefully monitored human studies on ginger or its equivalent are therefore needed. To show how effective it is as a gastroprotective agent, extracts must be used. To correctly ascertain the dosage and preparation of ginger in the protocol for additional clinical trials, dose-finding studies should be conducted. Mild gastrointestinal issues are uncommon side effects

of ginger consumption. complications like bruising, belching, heartburn, or. gastrointestinal discomfort, a rash, and flushing.^[10]

Negative events were. generally, not much higher in the ginger group compared to. referred to as the control group within a study. of some healthy volunteers who took a single oral dose of few mg. The main negative effect of two g of ginger was a mild gastrointestinal upset. outcome (Zick et al). Despite studies in the past suggesting that. bleeding a recent crossover study of some healthy participants. volunteers that took in few grams of dried ginger rhizome three times. Ginger had no impact on platelet aggregation when used daily for two weeks. pharmacokinetics or pharmacodynamics were unaffected. Warfarin few mg was administered as a solitary dose on day) also examined ginger's security. their meta-analysis's secondary goal. vomit and feel sick. of pregnancy and discovered that ginger posed no risk for adverse effects. or unfavourable pregnancies events. Ginger might be taken into consideration considering the evidence from this systematic review. a risk-free and potential effective female substitute. being pregnant and experiencing nausea and vomiting. It. It appears that some mg of ginger taken in smaller doses throughout the day is advantageous. to alleviate nausea. Ginger did not have any potential negative or side effects. pregnant women's experiences.^[11]

There is evidence for ginger's polyphenols. to specifically target the numerous signalling molecules that serve as its source of support. against complex human illnesses like cancer. Furthermore, most. Based solely on in, is the basis for all the known activities of ginger components. Except for a few clinical studies in the gastrointestinal, studies in vitro and in vivo. disorders in human subjects, in particular nausea and vomiting. and a small number in some other potential complications. in order to produce meaningful results, as much power. more extensive as a result. and under control. Studies on humans are necessary to prove this. because it is both cost- and safety-effective, its effectiveness as a gastroprotective agent. alternative. Dose-finding. Research should be done to be accurate. find the best ginger preparation and dosage [¹¹].

2.6 TURMERIC (*Curcuma longa*):



(Figure6: Turmeric)

The plant *Curcuma longa* L.'s rhizome, either fresh or dried, is used as turmeric. has been widely employed in conventional medicine. Turmeric (figure 6) is thought to have a wide range of therapeutic benefits in Ayurvedic medicine, an Indian traditional medical system. These benefits include boosting bodily energy, reducing gas, getting rid of worms, enhancing digestion, controlling menstruation, removing gallstones, and treating arthritis. It is also employed as an antiseptic for cuts, burns, and bruises as well as an antibacterial agent in many South Asian nations. Turmeric contains several phytochemicals, including turmerones and different polysaccharides; however, curcuminoids, a class of yellow pigments, are thought to be responsible for many the herb's therapeutic properties. Desmethoxycurcumin, bisdemethoxycurcumin, curcumin, and curcumin are all components of curcuminoids. The main curcuminoid of these, curcumin, has garnered the most attention in the scientific literature. Numerous signalling molecules have been shown to be targets of curcumin, with its antioxidant and anti-inflammatory properties thought to be the primary causes of most of its health benefits. Evidence exists to support its potential value in the treatment of [arthritis pain and metabolic syndrome], depression, and cognitive impairment. Preliminary research suggests that curcumin may be advantageous, and interest in its effects on digestive health is growing. According to a review by Lopresti curcumin has several effects on the Gastrointestinal system, including a bearing on intestinal microbiota, intestinal permeability, gut inflammation, and oxidative stress, as well as bacterial, parasitic, and fungal infections. These effects may make curcumin useful for treating gastrointestinal conditions. It was determined that there was overall evidence of efficacy in a meta-analyses of 5 clinical trials on the use of curcumin to lessen symptoms related to irritable bowel syndrome. But in all these trials, curcumin was a part of a multi-herbal combination, and most

studies consistently raised concerns about the risk of bias. Curcumin has also been shown to have positive effects on inflammatory bowel diseases and functional gastrointestinal disorders.^[12]

This week, randomised, double-blind, placebo-controlled trial's aim was to find out how a curcumin extract (Urgent) affected GI symptoms, mood, and general quality of life in adults who self-reported digestive complaints. Additionally, the effects of curcumin on the intestinal microbiota and small intestinal bowel overgrowth were investigated in order to identify the potential therapeutic mechanisms of action connected to this compound. Curcumin consumption was linked to changes in gut microbiota in a few animal studies and one small human study. For instance, curcumin supplementation for weeks increased the Firmicutes/Bacteroidetes ratio compared to a vehicle control in an animal study and supplementing with turmeric and curcumin for weeks in a human study was linked to an increase in detected species, respectively. In a second small study with eight healthy adults, curry with turmeric significantly accelerated small-bowel transit time and increased the area under the curve of breath hydrogen when compared to curry without turmeric. Despite this preliminary evidence of the Gastrointestinal effects of curcumin and its potential to affect intestinal microbiota, no trial has been conducted specifically looking at the Gastrointestinal effects of the curcumin extract, corpulent. urgent may be linked to improvements in digestive symptoms, and such changes may be caused by its influence on intestinal microbiota, according to previous research into turmeric and other curcumin extracts.^[13]

2.7 TRIPHALA (*Embolica officinalis*):




(Figure 7: Triphala)

Gastric cancer, the third most common cause of cancer-related death worldwide and the fifth most frequently diagnosed malignancy, continues to pose a serious threat to global health despite significant declines in both incidence and mortality over the past few decades. Chemotherapy, radiotherapy, and surgery are the standard therapeutic modalities for gastric cancer. Additionally, frequently used as adjuvant therapies to enhance treatment outcomes and lessen side effects are complementary and alternative medical interventions. The plant *Terminalia balearica* (Geert. *Phyllanthus emblicanin* Linn, Rob, and., a widely used traditional remedy, has been clinically effective for thousands of years in the treatment of a wide range of illnesses and disorders.^[13]

Tri Phala (figure 7) that has been finely ground, which contained equal amounts of *Terminalia chebulagic*, *Emblicanin officinalis*, and *Terminalia beleric*, was extracted with ultrapure water. Centrifugation and filtration through a point membrane filter. By using rotary in vivo antitumor assay, the filtrate solvent was eliminated.^[14] With a high rate of morbidity and mortality, a notoriously bad prognosis because of the disease's malignant nature, and few effective treatment options, gastric cancer continues to be a global health challenge despite recent advances in diagnosis and treatment. The main course of treatment for gastric cancer is a total surgical resection. Chemotherapy and adjuvant radiation therapy are frequently administered following surgery. Recurrence and metastasis, however, continue to be the main challenges to long-term survival.^[15] Therefore, cutting-edge techniques like immunotherapies have been developed to enhance patient prognosis. The overall survival of patients with gastric cancer has been shown to be improved by conventional treatments as well. However, these experience-based treatments are not always supported by scientific evidence. In fact, many traditional medical systems have developed therapeutic strategies for cancer.^[16]

III. SYNTHETIC AGENT:

3.1 DOMPERIDONE:




(Figure 8: Domperidone)

Domperidone, a water-insoluble, weakly basic anti-emetic drug, has a low oral bioavailability. The goal of this study was to increase this bioavailability. To speed up drug dissolution, drug adsorption onto the surface of Aerosol was accomplished using a solvent evaporation technique. Afterward, the adsorbates were created into floating gastro-retentive tablets to keep the medication in the stomach's acidic environment, which is ideal for drug dissolution.^[18] To choose the best ratio for the final formulation, various drug: adsorbent ratios were prepared and tested for their in-vitro dissolution rates. The tablets' weight uniformity, drug content, friability, hardness, thickness, floating characteristics, invitro dissolution rate, and drug release kinetics were all assessed after they had been made using the direct compression technique. The selected formulae significantly improved the bioavailability of domperidone (figure 8) when compared to commercially available conventional immediate-release tablets.^[19]

The sustained effect of drug release was enhanced by increasing the polymer concentration in tablets. The in-vivo studies revealed a significantly increased oral bioavailability of DMP in comparison to the commercially available monitor tablets. Formulae, which contains few percentages weight-weight Na Algo, and F8, which contains weight-weight Na Algo, demonstrated the best physical properties, floating properties, and release profiles.^[20]

3.2 RANITIDINE:



(figure9: Ranitidine)

An H₂ antagonist known as ranitidine (Zantac®) is used to treat stomach ulcers and heartburn. As soon as it was authorized for use in the US, ranitidine quickly rose to the top of the global sales charts. used over the counter and was marketed under both the private label and Zantac names until recently. as well as generic goods. samples contained the substance N-nitroso dimethylamine. of ranitidine, prompting the Food and Drug Administration to warn the public of the potential dangers involved Under typical storage conditions, in ranitidine rise and rise significantly. Higher temperatures that could happen during distribution and handling. And they discovered. In

April, the Food and Drug Administration made a statement considering these findings. Consumers were advised to stop using ranitidine (figure 9) because it would soon be taken off the market. of the merchandise. Cancers The Institutional Review Board at the University of Alabama in Birmingham evaluated this study. Public human subject research was not approved by the Review Board for Human Use. availability and the data source's de-identified nature. Report System, a database that includes reports of medication-related adverse events. reports of errors and complaints about the quality of products that cause negative outcomes. Eating contaminated food, inhaling contaminated air, or endogenously through the transformation of nitrosamine. precursors. In fact, there is a lot of proof that this connection exists. Even though this information is also available elsewhere, the formation is manuscript. (In the case of endogenous NDMA), assimilation, distribution, metabolism, and elimination. The gastrointestinal system's organs affect them primarily exposure to DNA damage-causing pathways increases the risk of cancer developmentGastrointestinal cancer is connected to ranitidine contamination. This exposure was asserted to be the cause by a mountain of evidence. Both in humans and animals, is linked to a higher risk of cancer. in order that. Future observational studies should better understand the nature of this relationship. Based on research, discuss issues relating to the scope and length of exposure.^[20]

3.3 SUCRALFATE:




(figure 10:Sucralfate)

The reduction of gastric ulcer recurrences is an ongoing significant issue. While a delay is an option, a duodenal ulcers recurrence after an initial attack. treatment with chemicals like bismuth compounds,". For gastric ulcers, this is not the case.

Treatment for patients who have recovered: maintenance. Various approaches to treating gastric ulcers have been tried. success with the use of ranitidine and cimetidine. Carbenoxolone, Caved-S, and pirenzepine. Both antacids and sucralfate are used. The participants in this study met the requirements. these standards.^[21]They had a and were mobile. By endoscopy, a benign gastric ulcer was demonstrated. over a few years old, provided informed biopsy. we're willing to cooperate, had consent, and were. capable of completing a diary card. The gastric ulcer had a when the study first started. mm in diameter (the estimated size of the ulcer). for calculating the ulcer, use open biopsy forceps. area where Blum could be seen was entirely within. Without involving the pyloric region or the stomach. there were no endoscopic indications of a duodenal bulb. large, flat, erratic, and numerous acute ulcers. mucosal defects) but had not bled inside. hours. two or more biopsy samples. a total of four from the ulcer wall, four from the ulcer area, and. Two of the adjacent mucosae demonstrated no. severe dysplasia or malignant tissue. The double was the primary aspect of this study. initial ulcers are administered both in blindness. With a, receive treatment and upkeep. plan for randomization starting at the beginning. a year after healing, from treatment. earliest ulcer. One of two active drugs was used during treatment. drugs, such as ranitidine or sucralfate. shown to be equally effective at healing ulcers. maintenance therapy with after healing. It was either sucralfate(figure 10) or a placebo.^[21]

3.4 OMEPRAZOLE:



(Figure 11: Omeprazole)


In this prospective study, the four-week omeprazole treatment for acid peptic disease was evaluated for effectiveness and patient satisfaction. Patient-reported outcome measures were used in this observational, post-marketing study. After obtaining informed consent, patients with symptoms who visited one of the five study locations throughout India and were given a prescription for oral omeprazole for at least four weeks were enrolled in the study. Using the Patient

Assessment of Gastrointestinal Disorder Symptom Severity Index questionnaire, study assessments included frequency and severity of symptoms as well as overall patient satisfaction. The Treatment Satisfaction Questionnaire for Medication was used by patients to rate their satisfaction with their therapy. Patients reported on few days respectively. Based on patient reports of adverse events, the safety of omeprazole (figure 11) was evaluated. The results of this real-world evidence study demonstrate the efficacy of omeprazole in the treatment of patients with (duodenal ulcer, gastric ulcer, and reflux oesophagitis) based on the patient's self-reported outcomes. These findings are in line with the body of knowledge and research, which indicates that omeprazole is a safe, efficient, and well-tolerated treatment for APD. In a research project by Lazenby LB et al. In unstudied heartburn patients with heartburn (gastritis, omeprazole significantly improved dyspepsia as measured by the Short-Form Leeds Dyspepsia Questionnaire). In our study, the overall scores significantly increased at baseline. In a Danish multicentred trial analysis, a high BMI, recent use of antacids or H₂-blockers, or nighttime pain were independently associated with a good omeprazole response to dyspepsia treatment, whereas the presence of nausea was associated with a poor omeprazole response, we noticed a significant decline in the number of patients reporting reflux.^[22]

They inhibit the growth of *Helicobacter pylori* and, when used in conjunction with antimicrobials, offer the most effective method of eliminating the bacterium. After four weeks and six weeks of treatment, respectively, In patients with ulcerative or erosive, eight-week PPI therapy has also been shown to improve endoscopically demonstrated healing. The authors also claim that PPIs taken daily are effective at preventing relapses. cited in Zimmermann AE et al. Omeprazole has been used successfully to treat erosive esophagitis, gastric ulcer, duodenal ulcer, *Helicobacter pylori* infection, and related conditions in children aged two months to few years at dosages. The initial dose that has been most frequently reported to treat esophagitis and ease symptoms seems to be few mg/kg per day. The authors concluded that, in uncontrolled clinical trials and case reports to date, omeprazole (figure 11) is effective and well tolerated for the acute and chronic treatment of oesophageal and PUD in children, particularly those who had not responded to prior treatment with H₂-receptor antagonists.^[23]

The adverse effects of particular interest were gastrointestinal intolerance, abdominal pain, diarrheic, nausea, vomiting, heartburn, giddiness, and regurgitations. Only four of the few patients—constipation, abdominal pain, headache, and diarrhoea—reported negative side effects. The severity of each event was minimal, and omeprazole therapy was well tolerated. Omeprazole is safe and well tolerated in all short-term studies, but more research is required to address the question of the long-term effects of hypergastrinemia brought on by severe acid suppression. The results of a four-week omeprazole few mg per day therapy in patients with APD were evaluated in this real-world clinical study, which was conducted in real medical settings^[23].

3.5 FAMOTIDINE:



(figure 12:Famotidine)

In critically ill patients, Gastroesophageal reflux and Gastroesophageal reflux disease are relatively common. According to reports, Duodenogastric reflux occurs in few percent patient. Inflammation of the oesophagus, ulcers, upper Gastrointestinal bleeding, bronchospasm, and aspiration pneumonia are all significant outcomes of Gastroesophageal reflux and Gastroesophageal reflux disease. Famotidine's (figure 12) impact on Gastroesophageal reflux and Gastroesophageal reflux disease was observed in our study, which used few-hour acid and bile reflux monitoring. Nineteen critically ill patients, whose ages ranged from thirty to seventy-five, were enrolled. Of these patients, ten were men and nine were women. Eleven of them had cerebral trauma, four had an acute cerebrovascular accident, one had an intracranial tumour, and three had respiratory failure with lung infection. Fasting for at least six hours, being on mechanical ventilation support, having never received enteral nutrition through a nasogastric tube, and having a serum bilirubin level below two milligrams per decilitres (mg/dL) were requirements for enrolment. Active gastroenteric bleeding, oesophageal and fundic varices, mechanical ileus, prior thoracic or abdominal


radiotherapy, oesophageal or gastric surgery, cholecystectomy, priorgastroesophageal reflux disease or gastroenteric dynamic disorders, and oesophageal or upper small intestinal Crohn's disease were among the exclusion criteria. Patients taking tiapride, erythromycin, atropine, theophylline, metoclopramide, or acid suppressants within three days were also disqualified.^[24]

In buffers, the pH monitor electrode was calibrated. The Billeted probe underwent calibration in a calibrating medium. Then, through the patient's nostril, two probes were taped together and inserted into the stomach. pH gradient change was used to identify the gastroesophageal junction. The probes were applied to the patients' faces after a chest X-ray ruled out torsion. The gastric residual volume was measured while famotidine was being administered on the third day after the nasogastric tube was placed in the stomach. Additionally, ventilation associated pneumonia, which is described in the informal guide for the diagnosis and management of nosocomial pneumonia established by the pulmonary division was noted. High rates of reflux may be caused by the following factors: Basic illnesses: Acute or chronic cerebral injury has been reported in the medical literature to decrease lower oesophageal sphincter pressure and delay gastric emptying when coupled with increased Posture. According to studies, reflux of duodenal juice is more common than pH studies alone would indicate in gastroesophageal reflux disease and the combined reflux of gastric and duodenal juices causes severe oesophageal mucosal damage. To simultaneously detect acid and bile reflux, we combined pH monitor.^[25]

Nineteen critically ill patients underwent the step-up for electrode positioning successfully. Our study found that the incidence of pathological Gastroesophageal reflux disease respectively, before the administration of famotidine, which was consistent with the medical literature. Acid and bile reflux were significantly improved following famotidine administration. One of the most widely used medication is famotidine. In our study, famotidine 40 mg intravenously twice daily would maintain oesophageal pH above for twenty hours. Following the administration of ranitidine, famotidine, and omeprazole, Parkman discovered elevated antral phase III migrating motor complexes, particularly in famotidine. According to a report, the Glasgow score was significantly correlated with delayed gastric emptying, which was in line with our findings. Additionally, we discovered that the fraction time of acid reflux was

positively correlated with gastric residual volume. Nasogastric tube use, H2 blockers, sedatives, muscle relaxants, and sedation are all known risk factors for ventilation-associated pneumonia. But neither aspiration pneumonia nor VAP occurred in our study. As a result, famotidine might not make pneumonia more common. Additionally, by lowering GER and DGER, it might make aspiration less likely. Further research with larger patient populations is required to clarify this relationship.^[25]

3.6 METOCLOPRAMIDE:




(Figure13: Metoclopramide)

Dopamine receptor antagonist metoclopramide has antiemetic and prokinetic properties. Its IUPAC name is 4-amino-5-chloro-N-(2-diethylamino ethyl)-2-methoxybenzamide. While the prokinetic properties improve the peristaltic waves of the stomach and intestine, speeding up the rate of absorption and, consequently, the rate of passage through the stomach, the antiemetic properties treat nausea and vomiting. Metoclopramide administration thus measurably increases gastric motility in healthy volunteers and, consequently, the rate of gastric emptying. Following oral administration, metoclopramide is swiftly and almost eliminated from the GI tract in healthy patients. Orally administered metoclopramide (figure 13) has a pharmacological effect that lasts for 1-2 hours and starts working 30 to 60 minutes after the subject takes the medication. So, following our baseline recordings in a fasting subject, metoclopramide was given, and we measured bio-impedance after a brief period of rest. This made sure that while the bio-impedance measurements were being taken, the subjects were receiving the full benefit of metoclopramide's pharmacological effects.^[26]

We enlisted 23 volunteers for this study. Everyone satisfied the following requirements: they were under the age of 30, had no history of gastrointestinal illness, no history of a condition that might have affected the function of the GI system (such as diabetes, Parkinson's disease,

amyloidosis, myotonic dystrophy, polymyositis, HIV infection, or cytomegalovirus infection), and they were not taking any medications that might have affected gastric activity. Participants also needed to be healthy weights and not be overweight, and they couldn't have lost a lot of weight in the three months prior to the study. In addition to these physical requirements, subjects had to be free of psychological issues such as stress, anxiety, depression, and mental illness because these conditions may modulate the endocrine and central nervous systems and affect gastric activity. Additionally, none of the subjects had any other endocrine disorders or food allergies that might have affected their ability to consume the food used in this trial. In the early follicular phase of their menstrual cycle, all the study participants underwent evaluation. A consent form that was approved by the Human Ethics Committee of the University of Guanajuato was signed by each subject who took part in the study. In accordance with the Declaration of Helsinki, the study was carried out. The position of the main peak in the frequency region, which is a common parameter for evaluating gastric motility, needs to be taken into consideration considering the combined frequency ranges' overall behaviours. With the precise measurement of gastric motility in the fasting state, the outcomes of our earlier research were verified. This study also showed that metoclopramide-induced gastric stress can be induced in systems using the bio-impedance technique. In this study, we showed that there was a decline in the median of the area under the FFT curve. The main peak would serve as a representative of the entire region in this case when the position of the main peak is used as a parameter for measuring gastric motility.^[26]

3.7 MESALAZINE:



(Figure 14: Mesalazine)

Among the drugs that gastroenterologists most frequently recommend, mesalazine is used in various contexts with varying degrees of agreement and disagreement. We set out to learn more about

how young gastroenterologists use mesalazine (figure 14) in their clinical work. In addition, of Inflammatory Bowel Disease-dedicated doctors continued to prescribe mesalazine for patients with IBD who were starting immunomodulators and/or biologics, compared to of non-dedicated doctors. In fact, of non-dedicated Inflammatory Bowel Disease doctors did not recognize mesalazine for colorectal cancer chemoprevention. Thirty one percent of Inflammatory Bowel Disease doctors use it primarily to prevent postoperative Crohn's disease recurrence in patients with the condition. Finally, few percent of patients with symptomatic, uncomplicated diverticular disease used mesalazine; few percent did not. Conclusions: This study revealed a variety of practices in mesalazine use daily, primarily for the treatment of Inflammatory Bowel Disease. To make its use clear, educational initiatives and ground-breaking research are required.^[26]

The study's participants provided their written informed consent before beginning. This survey offers a snapshot of how young Italian gastroenterologists are currently thinking and making decisions regarding the use of mesalazine, particularly in the therapeutic algorithms for Inflammatory Bowel Disease. Our findings show that all interviewed gastroenterologists have adequate knowledge of recommendations and uniform behaviour. For the treatment of mild diseases, a high degree of therapeutic agreement was attained. Given the recent enrichment of the drug pipeline for Inflammatory Bowel Disease, which can occasionally be confusing, especially for non-dedicated physicians, these results should be positively interpreted as there is a risk of overtreatment. This witness therefore attests that the positioning of mesalazine in the mild UC algorithm is still relevant today. On the other hand, we noticed notable differences between I and non-dedicated Inflammatory Bowel Syndrome doctors in the management of moderate to severe UC. These could be attributed to the vague definition of moderate UC, which leads to inconsistent clinical practice and the possibility of either under- or over-treating patients. A survey of Spanish gastroenterologists revealed that general gastroenterologists and Inflammatory Bowel Disease specialists had a high level of agreement with European guidelines in the management of mild to moderate UC. Less agreement was seen among general gastroenterologists, who used a

single daily dose of mesalazine as part of increased maintenance treatment.^[27]

In conclusion, this study shows how important it is to define disease activity in Inflammatory Bowel Disease patients in order to develop the most effective treatment plans. Mesalazine is still "an ace up the sleeve" for gastroenterologists in a variety of situations. However, there are still some important differences to be aware of, particularly in moderate-severe UC, in terms of doses and the concurrent use with second-line therapy. The knowledge of the use of mesalazine in all clinical settings must be standardized because most of the participants in this survey are trainees. Without distinction between specialized and non-specialized centres, we firmly believe that all young gastroenterologists should possess adequate knowledge of basic patient care. So that the use of mesalazine is more uniform, we hope to lay the groundwork for future research and advance fresh educational initiatives.^[27]

IV. CONCLUSION:

In light of the results of this study, which looked at the effects of having digestive problems, it is imperative to develop public health policies that include early intervention, specialized care, and psychological treatment. Avoiding barriers to accessing specialized mental health care for people with other associated diagnoses, such as gastrointestinal disorders, It is critical in this context. According to the evidence from this systematic review, ginger may be a safe and potentially helpful alternative for pregnant women experiencing nausea and vomiting. It appears that taking ginger twice daily can help with motion sickness. During pregnancy, ginger did not increase the risk of any side effects or negative outcomes. In order to use ginger as a treatment for multifactorial human diseases like cancer, it has been demonstrated that ginger and its polyphenols target a variety of signalling molecules. All Intestinal Bowel Syndrome; symptoms can be effectively treated with cumin extract. Cumin administration in patients with Intestinal Bowel Syndrome may have financial advantages given its low cost and simple availability. National Digital Medical Archive exposure is linked to an increased risk of cancer in both humans and animals, according to a wealth of evidence supporting this claim. Future observational studies should address questions regarding the scope and duration of exposure, guided by research regarding the presence of National Digital Medical Archive in ranitidine

products. This will help us better understand the nature of this relationship.

REFERENCES:

- [1]. Lovell RM, Ford AC., et al., Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Metaanalysis. *Clinical Gastroenterology and Hepatology*. 2012;10(7):712–721.
- [2]. Saito YA, Schoenfeld P, Locke GR., et al., The epidemiology of irritable bowel syndrome in North America: a systemic review. *The American journal of Gastroenterology*. 1910-1915.97
- [3]. Card T, Canavan C, West J., et al., The epidemiology of irritable bowel syndrome. *Clinical Epidemiology*. 2014;6:71–80.
- [4]. Rahman MM, Mahadeva S, Ghoshal UC., et al., Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. *World Journal of Gastroenterology*. 2017;23(37):6788–6801.
- [5]. Suhasini Dehury, Haribhaktisebadas., et al., Efficacy of peppermint oil in irritable bowel syndrome, *journal of medical sciences and health*, 2022:35-40
- [6]. Shams R, Oldfield EC, Copare J, Da J., et al., Peppermint Oil: Clinical Uses in the Treatment of Gastrointestinal Diseases. *JSM Gastroenterol Hepatol*. 2015;3(1):1036.
- [7]. Pittler MH, Ernst E, et al., Peppermint Oil for Irritable Bowel Syndrome: A Critical Review and Metaanalysis. *American Journal of Gastroenterology*. 1998;93(7):1131–1135.
- [8]. Ball, D., Ashley, G., & Stradling, H., et al., Exercise-induced Gastrointestinal disturbances: Potential amelioration with a ginger containing beverage. *proceeding of nutritional society (2015)74(OCE3)*, E186.
- [9]. Micklefield, G., Redeker, Y., Meister, V., Jung, O., Greving., et al., Effects of ginger on gastroduodenal motility *International Journal of Clinical Pharmacology and Therapeutics*, 1999, 37(7), 341–346.
- [10]. Stewart, J. J., Wood, M. J., Wood, C. D., & Mims, M. E., et al., Effects of ginger on motion sickness susceptibility and gastric function. *Pharmacology*, 1991, 42(2), 111–120

- [11]. Wu, K.-L., Rayner, C. K., Chuah, S.-K., et al., Effects of ginger on gastric emptying and motility in healthy humans. *European Journal of Gastroenterology & Hepatology*, 2008, 20(5), 436–440.
- [12]. F. Huang, M. Wang, T. Yang et al., “Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression,” *Journal of Cancer Research and Clinical Oncology*, vol. 140, no.11, pp. 1835–1848, 2014.
- [13]. L. Shi, Q. Zhou, J.Wu et al., “Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer,” *Cancer Immunology, Immunotherapy*, vol. 61, no. 12, pp. 2251–2259, 2012.
- [14]. M. Moehler, M. Delic, K. Goepfert et al., “Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives,” *European Journal of Cancer*, vol. 59, pp. 160–170, 2016.
- [15]. M. Rugge, R. M. Genta, F. Di Mario et al., “Gastric Cancer as Preventable Disease,” *Clinical Gastroenterology and Hepatology*, vol. 15, no. 12, pp. 1833–1843, 2017.
- [16]. M. Khushtar, H. H. Siddiqui, R. K. Dixit, M. S. Khan, D. Iqbal, and M. A. Rahman, “Amelioration of gastric ulcers using a hydro-alcoholic extract of Triphala in indomethacin-induced Wistar rats,” *European Journal of Integrative Medicine*, vol. 8, no. 4, pp. 546–551, 2016.
- [17]. V. Mishra, M. Agrawal, S. A. Onasanwo et al., “Anti-secretory and cyto-protective effects of chebulinic acid isolated from the fruits of Terminalia chebula on gastric ulcers,” *Phytomedicine*, vol. 20, no. 6, pp. 506–511, 2013.
- [18]. Le Berre, C.; Roda, G.; Nedeljkovic Protic, M.; Danese, S.; Peyrin-Biroulet, L., et al., Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. *Expert Opin. Biol. Ther.* 2020, 20, 363–378.
- [19]. Prantero, C.; Cottone, M.; Pallone, F.; Annese, V.; Franze, A.; Cerutti, R.; Porro, G.B.; Rotondo, S.G.; Andriulli, A. Ardizzone, S.; et al. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: Results of a randomized, multicenter trial. *Gastroenterology* 1999, 116, 521–526.
- [20]. Gisbert, J.P.; Gomollón, F.; Hinojosa, J.; Román, A.L.S., et al., Adherence of gastroenterologists to European Crohn’s and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain. *J. Crohns. Colitis* 2010, 4, 567–574.
- [21]. Mutmainah, Rinasusilowati., et al., Gastroprotective effect of combination of hot water extract of turmeric and cardamom pods and sambung leaf against aspirin-induced gastric ulcer model in rats. *Asian Pacific Journal of Tropical Biomedicine*, 2014-s500-s504.
- [22]. Shahram Agah, Amir Mehdi Tleb., et al., Cumin extracts for symptom control in patients with irritable bowel syndrome: A Case series, *Middle East Journal of Digestive Diseases* 2013-217-221.
- [23]. Adrian L, Lopresti., et al., Efficacy of a curcumin extract on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive compliance: a randomised, double blind, placebo-controlled BMC complementary medicine and therapies 2021 2-17.
- [24]. Ahmed E, Aboutale, Sayed I, et al., Formulation of domperidone in gastro-retentive floating tablets, *Journal of Innovation in Pharmaceutical and Biological Science*, 2016 82-92.
- [25]. Simon R, Bramhall, et al., Is there still a role for sucralfate in the treatment of gastritis, *World Journal of Meta-Analysis*, 2020 (1-3).
- [26]. Sharma P., et al., Reliving 25 years of experience with omeprazole in acid peptic disease. *Journal Assoc Physicians India* 2018 66:72-8.
- [27]. Ying Xin, Ning Dai, et al., The effect of famotidine on gastroesophageal refluxes in critically ill patients, *World Journal of Gastroenterology* (2003) 356-358